Repetitive levosimendan infusions for patients with advanced chronic heart failure in the vulnerable post-discharge period: the multinational randomized LeoDOR trial.

Gerhard PoelzlJohann AltenbergerJosep Comín-ColetJuan F DelgadoFrancesco FedeleMartín Jesús García-GonzálezFinn GustafssonJosep MasipZoltán PappStefan StörkHanno UlmerSarah MaierBojan VrtovecGerhard WikströmEndre ZimaAxel Bauernull null

Published in: European journal of heart failure (2023)

Among patients recently hospitalized with HF and reduced LVEF, intermittent levosimendan therapy did not improve post-hospitalization clinical stability.

Keyphrases

phase iii
cardiac surgery
phase ii
open label
double blind
clinical trial
study protocol
placebo controlled
high frequency
acute kidney injury
ejection fraction
high intensity
stem cells
randomized controlled trial
atrial fibrillation
smoking cessation